Retinitis pigmentosa is a genetic disease and a form of retinal dystrophy which causes cumulative impairment of the night vision and peripheral vision. Accompanied by the degeneration of rods and cones, RP treatment in London progresses with such symptoms as night blindness, the narrowing of the visual field, and the loss of central vision. Currently in stem cell therapy in London City is offering a unique solution to this encompassing condition.
Understanding Retinitis Pigmentosa
RP involves a very wide category of hereditary diseases of the retina and structure in the eye that is responsible for gathering light and changing it to neural impulses. The RHO, RPGR and CRB1 gene mutations cause the slow progressive death of the photoreceptors. When the rods are affected, the disease moves from night blindness and progresses to colour vision and central vision when cone cells are affected.
Stem Cell Therapy – London’s New Age Treatment for RP
London remains in the lead regarding the usage of stem cell technology in the treatment of RP, thus providing a new ray of light for patients. Here’s how stem cell therapy is being explored and applied in London to combat RP:
Innovative Stem Cell Applications
Retinal Progenitor Cells (RPCs): RPCs are cells extracted directly from the layer of the retina and can restore the photoreceptors of the retina. London’s leading research institutions are working on the application of RPCs to replace degenerate retinal cells and regain vision. These are obtained from the retina, grown in a culture, and then grafted back into the eye of the patient with a view of replacing the damaged tissues of the retina.
Induced Pluripotent Stem Cells (iPSCs): The iPSCs are the adult cells that are reprogrammed so as to become the pluripotent stem cells which have the ability to transform into different counterparts; among these are the retinal cells. The leading research institutions in London are employing iPSC technology to grow retinal cells from patients’ stem cells. This approach reduces the chances of the body rejecting the treatment and provides individual solutions for every patient.
Mesenchymal Stem Cells (MSCs): MSCs derived from various origins like bone marrow, adipose tissue etc are neuroprotective and anti-inflammatories in retinal models. They secrete growth factors which can promote the survival of existing retinal cells to counter the effects of degeneration.
Research and Clinical Trials in stem cell therapy to cure RP
The ophthalmological services are exploring the use of stem cell therapy for RP. They offer the safety and effectiveness of transplanted RPCs and also iPSCs in the recovery of the function of the retina. They are focused on stem cell research and more specifically on iPSC-derived retinal cells. Their research entails the development of complex procedures for the manufacturing and transplantation of retinal cells for the management of RP and its effects on vision recovery and retina functioning. New strategies of intervention are based on a synergy of gene therapy and stem cell technology. It focuses on entirely eradicating the genetic deformities that characterize RP and increasing the stem cell’s ability to regenerate respectively as a two-pronged treatment plan.
The Path Forward
As a major world commercial city, in a drive to further enhance clinical medicine London is at the forefront in offering Treatments for Retinitis Pigmentosa. At StemCellCure we stay committed to these changes and make sure that the people, suffering from RP, get treated through stem cell therapy.